Scientific and Ethical advisory Board (SEAB)
The Scientific and Ethical advisory Board (SEAB) is a consultative body which is formed to ensure and improve the scientific performance and the quality of results of DynaMORE. The SEAB advises the General Assembly and the Managing Board upon the request together with the Coordinator, and provides non-binding advice to the General Assembly and the Managing Board as decision making support. Members of the SEAB are invited to the annual GA meetings in order to monitor the progress within the work packages, to assess the scientific quality, and to give feedback to the Consortium members, but do not have a right to vote. The SEAB will also consider and mention any ethical issues which might require stronger attention or feedback.
The following renowned experts from the relevant scientific fields of DynaMORE have agreed to be part of the DynaMORE Scientific and Ethical Advisory Board:
- Prof. Dr. Angélique O. J. Cramer, School of Social and Behavioural Sciences, Department of Methodology and Statistics, Tilburg University, The Netherlands (expert in dynamic modelling of mental disorders)
- Prof. Dr. Tanja Jovanovic, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, USA (expert in empirical resilience studies)
- Prof. Dr. Thomas Berger, Institute of Psychology, University of Berne, Switzerland (expert in mental health interventions)
- Prof. Dr. Tade Spranger, Law School, University of Bonn, Germany (external ethics advisor)
Exploitation Management Committee (ExMC)
The ExMC will be chaired by IMEC, co-chaired by UMC-Mainz, and supported by SKU, UZH and KUL. The ExMC will meet three times a year via telephone conferences, and in person during the annual GA meetings.
The ExMC will set the IPR strategy, track IP, manage IPR, and adapt the IPR strategy throughout the project. The ExMC will also develop an exploitation and valorisation strategy, including preparatory activities such as a market study or competition analysis and sketching out several routes for exploitation such as (joint) product development by a single partner or part of the consortium, creation of a start-up endeavour, out-licensing of IPR and/or follow-up research. Based on its assessments, the ExMC will develop a product roadmap, with stakeholder involvement.